Professor | Zhifei Xu | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Zhifei Xu
Contact Information	xzfzjut@zju.edu.cn
Language ability	English, Chinese
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Zhifei Xu

Contact Information

xzfzjut@zju.edu.cn

Language ability

English, Chinese

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Pharmaceutical Sciences
Academic Background & Achievements	2020 PhD in Pharmacology: Zhejiang University Visiting Scholar: Cincinnati Children's Hospital Medical Center, USA Published 13 SCI papers as first or corresponding author Granted 4 invention patents Provided multiple drug cardiotoxicity treatment plans for clinical use Promoted research results in over ten hospitals Received Zhejiang Pharmaceutical Association Science and Technology Award (Second Prize)
Awards	Zhejiang University Outstanding Class Advisor (2021-2022) Zhejiang University School of Pharmacy Advanced Worker (2021) Zhejiang University Jiang Zhi Modern Biology and Pharmaceutical Technology Research Award for Innovation and Entrepreneurship Competition Excellent Instructor

University/Lab Affiliation and Title

Zhejiang University

Faculty

Pharmaceutical Sciences

Academic Background & Achievements

2020 PhD in Pharmacology: Zhejiang University
Visiting Scholar: Cincinnati Children's Hospital Medical Center, USA
Published 13 SCI papers as first or corresponding author
Granted 4 invention patents
Provided multiple drug cardiotoxicity treatment plans for clinical use
Promoted research results in over ten hospitals
Received Zhejiang Pharmaceutical Association Science and Technology Award (Second Prize)

Awards

Zhejiang University Outstanding Class Advisor (2021-2022)
Zhejiang University School of Pharmacy Advanced Worker (2021)
Zhejiang University Jiang Zhi Modern Biology and Pharmaceutical Technology Research Award for Innovation and Entrepreneurship Competition Excellent Instructor

Areas of Focus	Drug Toxicology Cardiovascular Pharmacology
Publications	Inhibition of PRKAA/AMPK (Ser485/491) Phosphorylation by Crizotinib Induces Cardiotoxicity via Perturbing Autophagosome-Lysosome Fusion, Xu Z, Pan Z, Jin Y, Gao Z, Jiang F, Fu H, Chen X, Zhang X, Yan H, Yang X, Yang B, He Q, Luo P, 2024 PTX3 from Vascular Endothelial Cells Contributes to Trastuzumab-induced Cardiac Complications, Xu Z, Gao Z, Fu H, Zeng Y, Jin Y, Xu B, Zhang Y, Pan Z, Chen X, Zhang X, Wang X, Yan H, Yang X, Yang B, He Q, Luo P, 2023 Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib, Xu Z, Jin Y, Gao Z, Zeng Y, Du J, Yan H, Chen X, Ping L, Lin N, Yang B, He Q, Luo P, 2022 High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity, Xu Z, Jin Y, Yan H, Gao Z, Xu B, Yang B, He Q, Shi Q, Luo P, 2018 Dasatinib causes keratinocyte apoptosis via inhibiting high mobility group box 1-mediated mitophagy, Gao Z, Hu Y, Fu H, Jiang F, Yan H, Yang X, Yang B, He Q, Luo P, Xu Z, 2023 Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells, Zhang Y, Gao Z, Pan Z, Fu H, Jiang F, Yan H, Yang B, He Q, Luo P, Xu Z, Yang X, 2023 Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib, Jiang L, Zeng Y, Ai L, Yan H, Yang X, Luo P, Yang B, Xu Z, He Q, 2022 Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation, Jin Y, Chen X, Gao Z, Shen X, Fu H, Pan Z, Yan H, Yang B, He Q, Xu Z, Luo P, 2021 JAK-STAT signaling as an ARDS therapeutic target: status and future trends, Zhang Y, Gao Z, Yan H, Yang B, He Q, Luo P, Xu Z, Yang X, 2023 Regulation of p53 stability as a therapeutic strategy for cancer, Xu Z, Wu W, Yan H, Hu Y, He Q, Luo P, 2021 Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy, Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X, 2020 Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management, Jiang L, Ping L, Yan H, Yang X, He Q, Xu Z, Luo P, 2020 Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies, Wang Z, Jiang L, Yan H, Xu Z, Luo P, 2021

Areas of Focus

Drug Toxicology
Cardiovascular Pharmacology

Publications

Inhibition of PRKAA/AMPK (Ser485/491) Phosphorylation by Crizotinib Induces Cardiotoxicity via Perturbing Autophagosome-Lysosome Fusion, Xu Z, Pan Z, Jin Y, Gao Z, Jiang F, Fu H, Chen X, Zhang X, Yan H, Yang X, Yang B, He Q, Luo P, 2024
PTX3 from Vascular Endothelial Cells Contributes to Trastuzumab-induced Cardiac Complications, Xu Z, Gao Z, Fu H, Zeng Y, Jin Y, Xu B, Zhang Y, Pan Z, Chen X, Zhang X, Wang X, Yan H, Yang X, Yang B, He Q, Luo P, 2023
Autophagic degradation of CCN2 (cellular communication network factor 2) causes cardiotoxicity of sunitinib, Xu Z, Jin Y, Gao Z, Zeng Y, Du J, Yan H, Chen X, Ping L, Lin N, Yang B, He Q, Luo P, 2022
High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity, Xu Z, Jin Y, Yan H, Gao Z, Xu B, Yang B, He Q, Shi Q, Luo P, 2018
Dasatinib causes keratinocyte apoptosis via inhibiting high mobility group box 1-mediated mitophagy, Gao Z, Hu Y, Fu H, Jiang F, Yan H, Yang X, Yang B, He Q, Luo P, Xu Z, 2023
Crizotinib induces pulmonary toxicity by blocking autophagy flux in alveolar epithelial cells, Zhang Y, Gao Z, Pan Z, Fu H, Jiang F, Yan H, Yang B, He Q, Luo P, Xu Z, Yang X, 2023
Decreased HMGB1 expression contributed to cutaneous toxicity caused by lapatinib, Jiang L, Zeng Y, Ai L, Yan H, Yang X, Luo P, Yang B, Xu Z, He Q, 2022
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation, Jin Y, Chen X, Gao Z, Shen X, Fu H, Pan Z, Yan H, Yang B, He Q, Xu Z, Luo P, 2021
JAK-STAT signaling as an ARDS therapeutic target: status and future trends, Zhang Y, Gao Z, Yan H, Yang B, He Q, Luo P, Xu Z, Yang X, 2023
Regulation of p53 stability as a therapeutic strategy for cancer, Xu Z, Wu W, Yan H, Hu Y, He Q, Luo P, 2021
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy, Ai L, Chen J, Yan H, He Q, Luo P, Xu Z, Yang X, 2020
Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management, Jiang L, Ping L, Yan H, Yang X, He Q, Xu Z, Luo P, 2020
Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies, Wang Z, Jiang L, Yan H, Xu Z, Luo P, 2021

Drug Toxicity Cardiovascular Diseases Mechanisms Treatment Strategies Cardiotoxicity Pharmacology Research Clinical Application Autophagy Heart

Xiangnan Zhang - Zhejiang University

Qiaojun He - Zhejiang University

Peihua Luo - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us